- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02266407
Surgical / Economic Effect of the Aquamantys System in Blood Management for Aseptic and Septic Revision TKA
The Surgical and Economic Effect of the Aquamantys System in Blood Management During and Following Aseptic and Septic Revision TKA
Study Overview
Status
Intervention / Treatment
Detailed Description
The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) represents a modern approach to reducing perioperative blood loss in patients undergoing total joint arthroplasty. Unlike standard electrocautery, which use monopolar radiofrequency energy, this technology uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. This eliminates the smoke and eschar formation seen with standard electrocautery. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
Suction is used to remove the saline from the surgical field with the treated tissue turning a light tan color. With normal use, the depth of penetration of this effect is typically less than 2mm. The technology is cleared by the US FDA (510(k)) and EU (CE Mark) for use on soft tissue & bone and will be used according to its intended packaging indications for use. The current assessment proposes a technique in which a disposable Aquamantys® hand piece is used to treat targeted areas which are bleeding or expected to bleed during surgery.
This postmarket study will assess the surgical and economic effectiveness of Aquamantys® System in managing intra-operative blood loss and transfusion rates in patients undergoing septic and aseptic revision TKA.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Markgröningen, Germany, 71706
- Orthopädische Klinik Markgröningen gGmbH
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- The patient is greater than 18 years of age
- Patients following failure of primary, unilateral TKA
- The degree of revision requires the use of an extended osteotomy for component removal
- Patient has participated in the informed consent process and has signed an Ethics Committee approved informed consent
Exclusion Criteria
- Patients presenting with a history of bleeding disorders and/or are on chronic blood anticoagulation therapy
- Patients presenting with an internal cardiac defibrillator
- Women who are pregnant
- Prisoner or transient
- Recent history of known narcotic abuse
- Any significant psychological disturbance past or present, that could impair the consent process or ability to complete subject self-report questionnaires
- Subject unwilling to undergo blood transfusion, if necessary
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: ASEPTIC Revision TKA & Aquamantys System
Single-stage revision TKA cases performed for aseptic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System.
These will be compared to in-house matched historic control using patients presenting with ASEPTIC failed primary TKA and revised without use of the Aquamantys® System.
|
The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring.
The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
|
|
Active Comparator: SEPTIC Revision TKA & Aquamantys System
Single-stage revision TKA cases performed for septic failure requiring an extended osteotomy for component removal and intra-operative blood management (bipolar sealing) with the Aquamantys® System.
These will be compared to in-house matched historic control using patients presenting with SEPTIC failed primary TKA revised without use of the Aquamantys® System.
|
The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring.
The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Blood Loss and Post-Operative Transfusion Rate
Time Frame: 14 days
|
To reduce blood loss and post-operative transfusion rates in patients undergoing total joint arthroplasty.
This will be achieved using the Aquamantys system.
The Aquamantys system provides transcollation which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
|
14 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Operative room and total hospital costs
Time Frame: 14 days
|
The data to be collected will include, but is not limited to: copies of the subjects' hospital bills, corresponding Explanation of Benefits (EOB), physician's bill, or itemized hospital bills.
The economic form(s) are collected and copies are provided to the sponsor.
|
14 days
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in hemoglobin and hematocrit from baseline (pre-op)
Time Frame: 14 days
|
As data is collected from subject record an analysis of this data will provide changes in hemoglobin levels
|
14 days
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Palaniswamy Vijay, PhD, Medtronic Surgical Technologies
- Principal Investigator: Joachim Singer, Dr.med., Orthopädische Klinik Markgröningen gGmbH
Publications and helpful links
General Publications
- Bierbaum BE, Callaghan JJ, Galante JO, Rubash HE, Tooms RE, Welch RB. An analysis of blood management in patients having a total hip or knee arthroplasty. J Bone Joint Surg Am. 1999 Jan;81(1):2-10. doi: 10.2106/00004623-199901000-00002.
- Pfeiffer M, Brautigam H, Draws D, Sigg A. A new bipolar blood sealing system embedded in perioperative strategies vs. a conventional regimen for total knee arthroplasty: results of a matched-pair study. Ger Med Sci. 2005 Dec 13;3:Doc10.
- Rosenberg AG. Reducing blood loss in total joint surgery with a saline-coupled bipolar sealing technology. J Arthroplasty. 2007 Jun;22(4 Suppl 1):82-5. doi: 10.1016/j.arth.2007.02.018.
- Marulanda GA, Krebs VE, Bierbaum BE, Goldberg VM, Ries M, Ulrich SD, Seyler TM, Mont MA. Hemostasis using a bipolar sealer in primary unilateral total knee arthroplasty. Am J Orthop (Belle Mead NJ). 2009 Dec;38(12):E179-83.
- Marulanda GA, Ragland PS, Seyler TM, Mont MA. Reductions in blood loss with use of a bipolar sealer for hemostasis in primary total knee arthroplasty. Surg Technol Int. 2005;14:281-6.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- TD-07711
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Infection of Total Knee Joint Prosthesis
-
Alberta Hip and Knee ClinicUniversity of CalgaryNot yet recruitingInfection of Total Hip Joint Prosthesis | Infection of Total Knee Joint Prosthesis
-
Pherecydes PharmaRecruitingInfection of Total Hip Joint Prosthesis | Infection of Total Knee Joint ProsthesisFrance
-
Technical University of MunichUnknownInfection of Total Knee Joint ProsthesisGermany
-
Rigshospitalet, DenmarkThe Lundbeck Foundation Centre for Fast-track Hip and Knee ArthroplastyWithdrawnInfection of Total Knee Joint ProsthesisDenmark
-
Zimmer BiometCompletedInfection of Total Knee Joint ProsthesisUnited States
-
University Hospital, ToulouseCompletedInfection of Total Hip Joint ProsthesisFrance
-
University of East AngliaDepuy, Inc.UnknownImplants | Infection of Total Hip Joint ProsthesisUnited Kingdom
-
Stryker Trauma GmbHOrthopedic Foot and Ankle Center, OhioTerminatedArthritis | Infection of Total Ankle Joint ProsthesisUnited States
-
University of MiamiNot yet recruitingProsthetic Joint Infection | Suture | Debridement With Prosthesis Retention | Prosthetic Joint Infections of Hip | Prosthetic Joint Infections of KneeUnited States
-
ProMedica Health SystemCompletedInfection of Total Hip Joint ProsthesisUnited States
Clinical Trials on Aquamantys System
-
Medtronic Surgical TechnologiesCompletedInflammation | Hemorrhage | Arthritis | Osteoarthritis | Surgery | Disability | InfectionUnited Kingdom
-
Stephen DuncanMedtronicCompleted
-
Hvidovre University HospitalCompleted
-
The Cleveland ClinicSalient Surgical TechnologiesCompleted
-
Northwell HealthCompletedSurgical Blood LossUnited States
-
Joint Implant Surgeons, Inc.Medtronic; Mount Carmel Health SystemCompletedArthritis, Rheumatoid | Osteonecrosis | Hip Dislocation, Congenital | Osteoarthritis, Hip | Joint Deformities, AcquiredUnited States
-
Duke UniversitySalient Surgical TechnologiesCompleted
-
University Hospital, Clermont-FerrandINNOPATH; MEDTRONIC labs provide the aquamantys® probes for the study.Unknown
-
Eastern Maine Medical CenterCompleted